Replies to post #410861 on Amarin Corp Plc (AMRN)

[Whalatane]

FFS. My recent purchases were at $1.18 .
AMRN is currently trading at $1.15 .
If it closes below $1, I will admit that you were right and I caught a falling knife ....being down 3c doesn't qualify .
I agree the technicals look bleak ....downtrending line still intact ...but the PPS also seems to attract buyers whenever its down in this area .
Sentiment is terrible ...as JR noted ...WS doesn't care about this stock

Fundamentally this stock is trading well below its real value ...Cash on hand is roughly $90m more than its current enterprise value .
The 2 risks that I see is that they can't grow sales in the UK and /or the MITIGATE study publishes some negative CV data ( as in event lines not separating at 2 yrs ) if they continued long term followup.

Kiwi
PS. OT for anyone reading this . My wife is a Nephrology PA and has patients who can't control their serum phosphorous levels .......a problem ARDX has developed a drug for ...awaiting approval by Dec 2023. Recent article in Science Direct

American Journal of Kidney Diseases
Tenapanor for the Treatment of Hyperphosphatemia in Japanese Hemodialysis Patients: A Randomized Phase 3 Monotherapy Study With an Up-titration Regimen
American Journal of Kidney Diseases
Available online 15 June 2023